The role of preoperative systemic treatment in patients with breast cancer

Sylwia Dębska-Szmich; Magdalena Krakowska; Urszula Czernek; Maja Habib-Lisik; Agnieszka Zięba; Piotr Potemski

doi:10.5114/wo.2016.60067

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2016
vol. 20

Send email

Copy url:

abstract:

Review paper

The role of preoperative systemic treatment in patients with breast cancer

Sylwia Dębska-Szmich

,

Magdalena Krakowska

,

Urszula Czernek

,

Maja Habib-Lisik

,

Agnieszka Zięba

,

Piotr Potemski

Contemp Oncol (Pozn) 2016; 20 (2): 93-101

DOI: https://doi.org/10.5114/wo.2016.60067

Online publish date: 2016/06/14

View full text Get citation

PlumX metrics:

The goal of preoperative pharmacotherapy in patients with breast cancer is to enable breast conserving surgery in stage T3N0-1M0 or radical mastectomy in patients with primary inoperative tumors (T1-4N0-3M0).

The choice of optimal treatment should be based not only on risk factors resulting from the stage but also on predicted cancer responsiveness to the treatment. The breast cancer subtypes defined by immunohistochemical profile (expression of ER, PR, HER2 and Ki67) are characterized by different responsiveness to therapy. Complete response confirmed by histopathological evaluation after neoadjuvant chemotherapy is a positive prognostic factor in some breast cancer subtypes. This marker is not of value in postmenopausal patients with ER/PR+ HER2– tumors, who are candidates for neoadjuvant hormone therapy. These patients have a good prognosis if in a histopathological report after surgery there are features such as pT1, pN0, Ki67 < 3%, and ER Allred score ≥ 3. The goal of the paper is to present current knowledge about preoperative pharmacotherapy of breast cancer.

keywords:

The role of preoperative systemic treatment in patients with breast cancer

Sylwia Dębska-Szmich , Magdalena Krakowska , Urszula Czernek , Maja Habib-Lisik , Agnieszka Zięba , Piotr Potemski

preoperative systemic treatment, complete pathological response, breast cancer subtypes

Sylwia Dębska-Szmich

,

Magdalena Krakowska

,

Urszula Czernek

,

Maja Habib-Lisik

,

Agnieszka Zięba

,

Piotr Potemski